[Development of new drugs targeting glial cells].
Kudo
Yoshihisa
Y
kudoy@ls.toyaku.ac.jp
Koizumi
Schuichi
S
Wada
Keiji
K
Hashimoto
Kenji
K
D000818:Animals; D001253:Astrocytes; D002491:Central Nervous System Agents; D016207:Cytokines; D015195:Drug Design; D018698:Glutamic Acid; D006801:Humans; D009457:Neuroglia; D018377:Neurotransmitter Agents; D043562:Receptors, G-Protein-Coupled; D016194:Receptors, N-Methyl-D-Aspartate; D018028:Receptors, Neurotensin; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D018048:Receptors, Purinergic P2; D058472:Receptors, Purinergic P2Y1; D012559:Schizophrenia / Q000209:etiology
D002491:Central Nervous System Agents; D016207:Cytokines; D018377:Neurotransmitter Agents; C546382:P2RY1 protein, human; D043562:Receptors, G-Protein-Coupled; D016194:Receptors, N-Methyl-D-Aspartate; D018028:Receptors, Neurotensin; D051236:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; D018048:Receptors, Purinergic P2; D058472:Receptors, Purinergic P2Y1; D018698:Glutamic Acid